20.04.2015 • News

Sartorius Stedim Biotech Buys BioOutsource

French biopharmaceutical industry contract supplier Sartorius Stedim Biotech (SSM) has acquired BioSource, a privately owned Glasgow, Scotland-based biotech firm for an undisclosed sum.

The Scottish company, in the market since 2007, employs 85 people and has annual sales of about €9 million.

BioOutsource provides contract testing services to clients in the global biopharmaceutical sector to monitor safety and quality of biological drugs and vaccines and also offers services to the biosimilars industry, where its assays are used in the early stages of drug comparison and comparability as well as for lot-release testing of modern therapeutics.

Aubagne-headquartered SSM said the acquisition will "help develop its service offering through the drug development pathway."

The French company with annual sales of €683.5 million has its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales offices. Its key manufacturing and research site is in Germany.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.